PMID- 35663309
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220729
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Serum miRNA Profile in Diabetic Patients With Ischemic Heart Disease as a 
      Promising Non-Invasive Biomarker.
PG  - 888948
LID - 10.3389/fendo.2022.888948 [doi]
LID - 888948
AB  - The increasing morbidity and mortality of type 2 diabetic mellitus (T2DM) 
      patients with ischemic heart disease (IHD) highlight an urgent need to identify 
      early biomarkers, which would help to predict individual risk of development of 
      IHD. Here, we postulate that circulating serum-derived micro RNAs (miRNAs) may 
      serve as potential biomarkers for early IHD diagnosis and support the 
      identification of diabetic individuals with a predisposition to undergo IHD. We 
      obtained serum samples from T2DM patients either with IHD or IHD-free and 
      analysed the expression levels of 798 miRNAs using the NanoString nCounter 
      technology platform. The prediction of the putative miRNAs targets was performed 
      using the Ingenuity Pathway Analysis (IPA) software. Gene Ontology (GO) analysis 
      was used to identify the biological function and signalling pathways associated 
      with miRNA target genes. Hub genes of protein-protein interaction (PPI) network 
      were identified by STRING database and Cytotoscape tool. Receiver operating 
      characteristic (ROC) analysis was used to assess the diagnostic value of 
      identified miRNAs. Real-time quantitative polymerase chain reaction (qRT-PCR) was 
      used for nCounter platform data validation. Our data showed that six miRNAs 
      (miR-615-3p, miR-3147, miR-1224-5p, miR-5196-3p, miR-6732-3p, and miR-548b-3p) 
      were significantly upregulated in T2DM IHD patients compared to T2DM patients 
      without IHD. Further analysis indicated that 489 putative target genes mainly 
      affected the endothelin-1 signalling pathway, glucocorticoid biosynthesis, and 
      apelin cardiomyocyte signalling pathway. All tested miRNAs showed high diagnostic 
      value (AUC = 0.779 - 0.877). Taken together, our research suggests that 
      circulating miRNAs might have a crucial role in the development of IHD in 
      diabetic patients and may be used as a potential biomarker for early diagnosis.
CI  - Copyright (c) 2022 Bielska, Niemira, Bauer, Sidorkiewicz, Szalkowska, Skwarska, 
      Raczkowska, Ostrowski, Gugala, Dobrzycki and Kretowski.
FAU - Bielska, Agnieszka
AU  - Bielska A
AD  - Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
FAU - Niemira, Magdalena
AU  - Niemira M
AD  - Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
FAU - Bauer, Witold
AU  - Bauer W
AD  - Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
FAU - Sidorkiewicz, Iwona
AU  - Sidorkiewicz I
AD  - Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
FAU - Szalkowska, Anna
AU  - Szalkowska A
AD  - Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
FAU - Skwarska, Anna
AU  - Skwarska A
AD  - Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 
      Houston, TX, United States.
FAU - Raczkowska, Justyna
AU  - Raczkowska J
AD  - Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
FAU - Ostrowski, Damian
AU  - Ostrowski D
AD  - Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
FAU - Gugala, Kamil
AU  - Gugala K
AD  - Department of Invasive Cardiology, Medical University of Bialystok, Bialystok, 
      Poland.
FAU - Dobrzycki, Slawomir
AU  - Dobrzycki S
AD  - Department of Invasive Cardiology, Medical University of Bialystok, Bialystok, 
      Poland.
FAU - Kretowski, Adam
AU  - Kretowski A
AD  - Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
AD  - Department of Endocrinology, Diabetology and Internal Medicine, Medical 
      University of Bialystok, Bialystok, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220518
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Biomarkers)
RN  - 0 (MIRN1224 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Biomarkers
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/genetics
MH  - Gene Expression Profiling
MH  - Humans
MH  - *MicroRNAs/genetics
MH  - *Myocardial Ischemia/complications/diagnosis/genetics
PMC - PMC9157821
OTO - NOTNLM
OT  - biomarker
OT  - diabetes
OT  - ischemic heart disease
OT  - miRNA
OT  - miRNA profiling
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/07 06:00
MHDA- 2022/06/09 06:00
PMCR- 2022/01/01
CRDT- 2022/06/06 13:57
PHST- 2022/03/03 00:00 [received]
PHST- 2022/04/08 00:00 [accepted]
PHST- 2022/06/06 13:57 [entrez]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.888948 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 May 18;13:888948. doi: 
      10.3389/fendo.2022.888948. eCollection 2022.